Barclays Cuts Medpace (NASDAQ:MEDP) Price Target to $500.00

Medpace (NASDAQ:MEDP) had its target price lowered by Barclays from $525.00 to $500.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an underweight rating on the stock.

Other research analysts have also issued research reports about the company. Truist Financial decreased their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday. Mizuho set a $660.00 price objective on shares of Medpace in a research report on Friday, January 9th. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a report on Tuesday. TD Cowen reissued a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Finally, BMO Capital Markets set a $460.00 price target on shares of Medpace in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $487.36.

Medpace Stock Performance

Shares of Medpace stock opened at $428.03 on Wednesday. The firm has a 50-day simple moving average of $567.52 and a two-hundred day simple moving average of $537.72. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The company has a market cap of $12.15 billion, a P/E ratio of 27.98, a price-to-earnings-growth ratio of 1.99 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s quarterly revenue was up 32.0% on a year-over-year basis. During the same period last year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts forecast that Medpace will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 270,533 shares of company stock worth $163,122,826. Insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quent Capital LLC acquired a new stake in shares of Medpace during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. acquired a new stake in Medpace during the third quarter worth $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace during the 4th quarter worth $30,000. Finally, Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth about $30,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.